Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 10,300 shares, a growth of 30.4% from the August 30th total of 7,900 shares. Based on an average trading volume of 25,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.4% of the company’s stock are sold short.
Separately, ValuEngine upgraded Eyegate Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.
In other Eyegate Pharmaceuticals news, major shareholder Armistice Capital Master Fund acquired 605,001 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was purchased at an average cost of $3.12 per share, for a total transaction of $1,887,603.12. Also, insider Stephen From sold 127,355 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $0.24, for a total value of $30,565.20. The disclosure for this sale can be found here. Insiders have sold a total of 166,154 shares of company stock valued at $39,877 over the last 90 days. Corporate insiders own 47.50% of the company’s stock.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Susquehanna International Group LLP acquired a new position in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 222,297 shares of the specialty pharmaceutical company’s stock, valued at approximately $53,000. Susquehanna International Group LLP owned 0.49% of Eyegate Pharmaceuticals at the end of the most recent quarter.
NASDAQ EYEG traded down $0.28 during trading on Friday, reaching $3.30. 5,001 shares of the company’s stock were exchanged, compared to its average volume of 34,760. Eyegate Pharmaceuticals has a fifty-two week low of $2.25 and a fifty-two week high of $9.60. The firm has a market capitalization of $10.07 million, a PE ratio of -0.73 and a beta of 2.12. The company’s fifty day simple moving average is $2.71 and its 200-day simple moving average is $0.87.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.60) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.15. As a group, sell-side analysts expect that Eyegate Pharmaceuticals will post -1.95 earnings per share for the current fiscal year.
Eyegate Pharmaceuticals Company Profile
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
See Also: Capital Gains Distribution
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.